Borderline resectable pancreatic cancer: on the edge of survival (Q37277969)

19 August 2017

1 reference

title

Borderline resectable pancreatic cancer: on the edge of survival (English)

1 reference

19 August 2017

1 reference

Gregory M Springett

1

1 reference

19 August 2017

Sarah E Hoffe

series ordinal

2

1 reference

19 August 2017

publication date

1 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

15

1 reference

19 August 2017

issue

4

1 reference

19 August 2017

page(s)

295-307

1 reference

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Neoadjuvant therapy in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Pancreatic cancer presenting as a Sister Mary Joseph's nodule: case report and update of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Evidence-based diagnosis and staging of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Feasibility study of the treatment of primary unresectable carcinoma of the pancreas with 103Pd brachytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Gemcitabine and radiosensitization in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Respiration-induced movement of the upper abdominal organs: a pitfall for the three-dimensional conformal radiation treatment of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

The correlation between internal and external markers for abdominal tumors: implications for respiratory gating

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Physical aspects of a real-time tumor-tracking system for gated radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Patient training in respiratory-gated radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500404

10.1177/107327480801500404

21 January 2018

Identifiers

DOI

0 references

1 reference